Real-world cohort study highlights tolerability of trastuzumab deruxtecan, with moderate adverse events in patients with HER2+ metastatic breast cancer.
Key Points
Trastuzumab deruxtecan shows acceptable tolerability in a cohort of patients with HER2+ metastatic breast cancer.
Common adverse events included fatigue (95.3%), with significant numbers requiring dose reductions and treatment discontinuation.
The study supports trastuzumab deruxtecan's efficacy, matching results observed in clinical trials, and confirms its clinical utility.
Findings call for continued research on real-world tolerability and monitoring adverse events in long-term treatment.